Description

Zimeta is a prescription animal drug product containing 500 mg dipyrone/mL and is intended for intravenous injection once or twice daily (every 12 hours) for up to three days.

Usage

Zimeta, a dipyrone injection is used to control fever, known as pyrexia, in horses. Zimeta belongs to the pyrazolone class of non-steroidal anti-inflammatory (NSAID) drugs and is the first injectable dipyrone product to receive FDA approval for use in horses .

Dosage and Administration

Zimeta is a prescription animal drug product containing 500 mg dipyrone/mL and is intended for intravenous injection. The recommended dose in horses is once or twice daily, at 12-hour intervals, for up to three days, at a dosage of 30 mg/kg of body weight (13.6 mg/lb).

The overall number of doses and duration of treatment with Zimeta is dependent on the response observed (fever reduction). Zimeta may be re-administered based on recurrence of fever for up to 3 days. Do not exceed twice a day dosing. Zimeta is provided in a multi-dose vial.

Notes:

• Federal law restricts this drug to use by or on the order of a licensed veterinarian..

Side Effects

In a clinical field study, 138 horses of various breeds, ranging in age from 1 to 32 years of age, were treated with one or more doses of Zimeta. The most common adverse reactions were elevated serum sorbitol dehydrogenase (SDH), hypoalbuminemia, gastric ulcers, hyperemic mucosa of the right dorsal colon, and prolonged activated partial thromboplastin time (APTT)..

Precautions

Zimeta is contraindicated in horses with a known sensitivity to dipyrone. Concurrent administration of potentially nephrotoxic drugs should be carefully approached or avoided.

Since many NSAIDs have the potential to produce gastrointestinal ulcerations and/or gastrointestinal perforation, concomitant use of Zimeta with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided.

Treatment administrators and caregivers should be aware of the potential for adverse reactions and the clinical signs associated with NSAID intolerance, which may include colic, diarrhea, and decreased appetite. Zimeta has been shown to cause prolongation of coagulation parameters in horses.

Caution should be used in horses at risk for hemorrhage. The safe use of Zimeta in horses less than 3 years of age, horses used for breeding, or in pregnant or lactating mares has not been evaluated.

Precautions should be employed by practitioners when handling and using loaded syringes to prevent accidental self-injection, as epidemiological studies have indicated that dipyrone can cause agranulocytosis in humans.

Zimeta™ (dipyrone injection) should not be used more frequently than every 12 hours.

For use in horses only. Do not use in horses with a hypersensitivity to dipyrone, horses intended for human consumption or any food producing animals, including lactating dairy animals.

Not for use in humans, avoid contact with skin and keep out of reach of children.

Take care to avoid accidental self-injection and use routine precautions when handling and using loaded syringes.

Prior to use, horses should undergo a thorough history and physical examination.

Monitor for clinical signs of coagulopathy and use caution in horses at risk for hemorrhage.

Concomitant use with other NSAIDs, corticosteroids and nephrotoxic drugs, should be avoided. As a class, NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. The most common adverse reactions observed during clinical trials were Elevated Serum Sorbitol Dehydrogenase (SDH), Hypoalbuminemia and Gastric Ulcers.

Product labels

The drug labels on this website represent drug information listings as submitted to the FDA.The drug labels on this website have not been altered or modified by EquiMed. The drug labels on this website may not be the most current or identical to the current labels shipped with the product. Contact your veterinarian or the manufacturer for the latest information on this drug or medication prior to use.